Seamless Phase IIa/IIb and enhanced dose-finding adaptive design

Area of Science:

• Drug development and clinical trial design.
• Pharmaceutical research and regulatory science.

Background:

• Drug development faces challenges with slow patient enrollment in specific populations.
• Conventional dose-finding (DF) study designs may lack efficiency in identifying optimal doses for Phase III trials.

Purpose of the Study:

• To propose and evaluate an adaptive study design combining proof of concept (POC) and dose-finding (DF) phases.
• To enhance the efficiency and power of dose selection for subsequent Phase III trials.
• To enable economical testing of multiple drug doses.

Main Methods:

• Simulation of hypothetical examples to compare adaptive design with conventional DF designs.
• Modeling of overall quantitative representation of efficacy, safety, and tolerability.
• Focus on adaptive strategies for efficient dose testing.

Main Results:

• The proposed adaptive design tested more active doses compared to conventional methods.
• Achieved higher statistical power in identifying optimal doses.
• Demonstrated comparable or smaller sample sizes and shorter overall study durations for POC and DF phases.

Conclusions:

• Adaptive designs integrating POC and DF studies offer a more efficient approach to drug development.
• This strategy improves the probability of selecting optimal doses for Phase III trials.
• The adaptive design facilitates economical testing of multiple doses while optimizing study timelines and resources.